KP Tissue Releases Third Quarter 2026 Financial Results

Higher earnings at Kruger Products coincided with lower operating cash flow and a delay to its planned tissue facility.

Rhea-AI Summary

KP Tissue (KPTSF) reported third-quarter net income of $3.1 million as its investment in Kruger Products delivered higher earnings.

KPT holds 12.0% of Kruger Products, whose Q3 2026 revenue rose 5.1% to $589.7 million. Adjusted EBITDA, a non-GAAP earnings measure excluding financing, taxes and certain other items, increased 9.1% to $93.5 million. Net income attributable to Kruger Products reached $27.708 million versus $14.546 million. Operating cash flow fell to $86.469 million from $113.336 million.

Kruger Products expects Q4 adjusted EBITDA slightly below Q3 but above Q4 2025, assuming a similar tariff environment. It expects escalating input costs and has deferred its new tissue facility location decision pending greater economic and trade certainty; operations will not begin in 2028 as previously anticipated. KPT declared a $0.21 quarterly dividend, payable January 15, 2027.

14 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 12 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointKruger Products Q3 revenue increased 5.1% to $589.7 million, supporting KPT's underlying investment.
• Moderate pointKruger Products Q3 adjusted EBITDA increased 9.1% to $93.5 million year over year.
• Moderate pointKruger Products Q3 attributable net income rose to $27.708 million from $14.546 million.
• Moderate pointKPT Q3 net income was $3.1 million, including $3.3 million from its share of Kruger Products earnings.
• Moderate pointKruger Products Q3 operating income increased to $59.813 million from $53.222 million.

9 minor points

• Minor pointKruger Products Q3 interest and finance costs declined to $18.707 million from $21.569 million.
• Minor pointKruger Products Q3 cost of sales improved to 81.6% of revenue from 82.0%.
• Minor pointKruger Products Q3 selling and administrative expenses improved to 8.3% of revenue from 8.5%.
• Minor pointKruger Products nine-month revenue increased to C$1,685.193 million from C$1,643.335 million.
• Minor pointKruger Products nine-month operating income increased to C$175.643 million from C$120.152 million.
• Minor pointKruger Products nine-month attributable net income increased to C$69.637 million from C$52.088 million.
• Minor pointKruger Products long-term debt excluding current maturities declined to C$1,055.242 million from C$1,074.646 million at year-end.
• Minor pointKruger Products current debt maturities declined to C$89.923 million from C$98.649 million at year-end.
• Minor point. Forward-looking: it has not happened yet and may not happen.Kruger Products is considering productivity initiatives and pricing adjustments to mitigate rising costs.

Negative

• Moderate pointKruger Products' new tissue facility is delayed beyond its anticipated 2028 start; location selection awaits greater economic and trade certainty.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Kruger Products expects escalating input costs and increased inflationary pressure.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Kruger Products expects Q4 adjusted EBITDA slightly below Q3 but above Q4 2025, assuming similar tariffs.
• Moderate pointKruger Products Q3 operating cash flow fell to C$86.469 million from C$113.336 million.
• Minor pointKruger Products nine-month operating cash flow declined to C$202.745 million from C$204.965 million.

7 minor points

• Minor pointKruger Products cash declined to C$176.407 million at September 30, 2026, from C$196.094 million at year-end.
• Minor pointKruger Products Q3 cost of sales rose to C$481.019 million from C$459.988 million.
• Minor pointKruger Products Q3 selling and administrative expenses rose to C$48.823 million from C$47.906 million.
• Minor pointKruger Products Q3 income tax expense increased to C$12.329 million from C$9.433 million.
• Minor pointKruger Products Q3 depreciation increased to C$31.448 million from C$30.259 million.
• Minor pointKruger Products Q3 amortization increased to C$2.233 million from C$2.190 million.
• Minor pointKruger Products faced higher freight rates, manufacturing overhead and warehousing costs versus Q3 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Maintaining profitable growth despite uncertain economic outlook

Mississauga, Ontario--(Newsfile Corp. - November 11, 2026) - KP Tissue Inc. (TSX: KPT) (KPT) reports the Q3 2026 financial and operational results of KPT and Kruger Products Inc. (Kruger Products). Kruger Products is Canada's leading manufacturer of quality tissue products for the Consumer market (Cashmere®, Purex®, SpongeTowels®, Scotties®, White Swan® and Bonterra®) and the Away-From-Home (AFH) market and continues to grow in the U.S. Consumer tissue business with the White Cloud® brand and premium private label products. KPT currently holds a 12.0% interest in Kruger Products.

Kruger Products Q3 2026 Business and Financial Highlights

• Revenue was $589.7 million in Q3 2026 compared to $561.1 million in Q3 2025, an increase of $28.6 million or 5.1%.
• Adjusted EBITDA¹ was $93.5 million in Q3 2026 compared to $85.7 million in Q3 2025, an increase of 9.1%.
• Net income was $27.7 million in Q3 2026 compared to $14.6 million in Q3 2025, an increase of $13.1 million.
• Declared a quarterly dividend of $0.21 per share to be paid on January 15, 2027.

"Our continued strong execution in the third quarter of 2026 has led us to deliver more than three consecutive years of profitable growth," stated Kruger Products' and KP Tissue's Chief Executive Officer, Dino Bianco. "Revenue and Adjusted EBITDA¹ increased 5.1% and 9.1%, respectively, year-over-year despite an ongoing uncertain economic environment. We are particularly pleased with our robust sales growth in the U.S. In Canada, sales also grew in the third quarter, as we continued to invest in our brands. We remain focused on executing our share recovery plan which should deliver improving shares."

"Looking ahead, we expect to navigate escalating input costs and increased inflationary pressure. Among the cost mitigation measures under consideration are productivity initiatives and pricing adjustments. We continue to make progress on our new TAD facility project, however, a final location decision will be deferred until there is greater certainty in the economic and trade environment. Accordingly, we anticipate that the new TAD facility will be delayed and not commence operations in 2028," Mr. Bianco added.

Outlook for Q4 2026
Assuming a similar tariff environment, we expect Q4 2026 Adjusted EBITDA¹ to be slightly below Q3 2026, while remaining above the same quarter last year.

Kruger Products Q3 2026 Financial Results
Revenue was $589.7 million in Q3 2026 compared to $561.1 million in Q3 2025, an increase of $28.6 million or 5.1%. The increase in revenue was primarily due to higher sales volume in the Consumer segment along with favourable selling prices in the Consumer U.S. business.

Cost of sales was $481.1 million in Q3 2026 compared to $460.0 million in Q3 2025, an increase of $21.1 million or 4.6%. The increase in cost of sales was primarily due to increased sales volumes, additional manufacturing overhead spend to invest in our sites as well as the unfavourable impact of foreign exchange fluctuations on U.S. dollar costs compared to the year ago quarter, partially offset by lower pulp costs. Freight rates increased due to higher diesel prices and carrier capacity constraints, while warehousing costs increased compared to Q3 2025 primarily as a result of handling costs related to higher sales volume. As a percentage of revenue, cost of sales was 81.6% in Q3 2026 compared to 82.0% in Q3 2025.

Selling, general and administrative (SG&A) expenses were $48.8 million in Q3 2026 compared to $47.9 million in Q3 2025, an increase of $0.9 million or 1.9%. The increase was primarily due to additional investment in IT, foreign exchange losses compared to gains in the prior year and higher compensation costs. This was partially offset by lower advertising and promotion spend compared to the year ago quarter. As a percentage of revenue, SG&A expenses were 8.3% in Q3 2026 compared to 8.5% in Q3 2025.

Adjusted EBITDA¹ was $93.5 million in Q3 2026 compared to $85.7 million in Q3 2025, an increase of $7.8 million or 9.1%. The increase was primarily due to higher sales volumes and selling prices along with favourable pulp costs, partially offset by higher freight rates, manufacturing overhead spend and warehousing costs.

Net income was $27.7 million in Q3 2026 compared to $14.6 million in Q3 2025. This was primarily due to higher Adjusted EBITDA¹, foreign exchange gain and lower interest expense. This was partially offset by higher income tax expense, higher depreciation and amortization, and higher income from non-controlling interest.

Kruger Products Q3 2026 Liquidity
Total liquidity, representing cash and availability under the revolving credit agreements, was $434.2 million as of September 30, 2026.

KPT Q3 2026 Financial Results
KPT had net income of $3.1 million in Q3 2026. Included in net income was $3.3 million representing KPT's share of Kruger Products' net income, a dilution gain of $0.1 million and depreciation expense of $0.3 million related to adjustments to carrying amounts on acquisition.

Dividends on Common Shares
The Board of Directors of KPT declared a quarterly dividend of $0.21 per share to be paid on January 15, 2027 to shareholders of record at the close of business on December 31, 2026.

Additional Information
For additional information please refer to Management's Discussion and Analysis (MD&A) of KPT and Kruger Products for the third quarter ended September 30, 2026 available on SEDAR+ at www.sedarplus.ca or our website at www.kptissueinc.com.

Third Quarter Results Conference Call Information
KPT will hold its third quarter conference call on Wednesday, November 11, 2026 at 8:30 a.m. Eastern Time.
Via telephone: 1-888-699-1199 or 416-945-7677
Via internet: www.kptissueinc.com

Presentation material referenced during the conference call will be available at www.kptissueinc.com.

A rebroadcast of the conference call will be available until midnight, November 18, 2026, by dialing 1-888-660-6345 or 289-819-1450 and entering passcode 13547.

The replay of the webcast will remain available on the website until midnight, November 18, 2026.

About KP Tissue Inc.
KPT was created to acquire, and its business is limited to holding, a limited equity interest in Kruger Products, which is accounted for as an investment on the equity basis. KPT currently holds a 12.0% interest in Kruger Products. For more information visit www.kptissueinc.com.

About Kruger Products Inc.
Kruger Products is Canada's leading manufacturer of quality tissue products for household, industrial and commercial use. Kruger Products serves the Canadian consumer market with such well-known brands as Cashmere®, Purex®, SpongeTowels®, Scotties®, White Swan® and Bonterra®. In the U.S., Kruger Products manufactures the White Cloud® brand, as well as many private label products. The Away-From-Home division manufactures and distributes high-quality, cost-effective product solutions to a wide range of commercial and public entities. Kruger Products has approximately 3,000 employees and operates ten FSC® COC-certified (FSC® C-104904) production facilities in North America. For more information visit www.krugerproducts.ca.

Non-GAAP Financial Measures
This press release uses certain non-GAAP financial measures which Kruger Products believes provide useful information to management of Kruger Products and the readers of the financial information in measuring the financial performance and financial condition of Kruger Products. These measures do not have a standardized meaning prescribed by GAAP and therefore may not be comparable to similarly titled measures presented by other companies. An example of such a measure is Adjusted EBITDA. Adjusted EBITDA is not a measurement of operating performance computed in accordance with GAAP and should not be considered as a substitute for operating income, net income or cash flows from operating activities computed in accordance with GAAP. "Adjusted EBITDA" is calculated by Kruger Products as net income (loss) before (i) interest expense and other finance costs, (ii) income taxes, (iii) depreciation, (iv) amortization, (v) loss on sale of non-financial assets, (vi) loss (gain) on disposal of property, plant and equipment, (vii) foreign exchange loss (gain), (viii) costs related to restructuring activities and (ix) other (income) expense. A reconciliation of Adjusted EBITDA to the relevant reported results can be found in the Segment and Geographic Results table of this press release.

Forward-Looking Statements
Certain statements in this press release about KPT's and Kruger Products' current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements or any other future events or developments constitute forward-looking statements. Forward-looking statements in this press release include, but are not limited to, items such as plans to build a new TAD tissue plant and its expected annual production capacity, expected date for starting production, the expected financing structure of the project and certain anticipated benefits of the project. The words "may", "will", "would", "should", "could", "expects", "plans", "intends", "trends", "indications", "anticipates", "believes", "estimates", "predicts", "likely" or "potential" or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. The forward-looking statements are based on certain key expectations and assumptions made by KPT or Kruger Products, in respect of the plans to build a new TAD tissue plant, and obtaining financing on acceptable terms for the project. Although KPT and Kruger Products believe that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking statements since no assurance can be given that such expectations and assumptions will prove to be correct.

The outlook provided in respect of Adjusted EBITDA¹ for Q4 2026 is forward-looking information and is based on the assumptions and subject to the risk and uncertainties referred to below. The purpose of the outlook is to provide the reader with an indication of management's expectations, at the date of this press release, regarding Kruger Products' future financial performance. Readers are cautioned that this information may not be appropriate for other purposes.

Many factors could cause Kruger Products' actual results, level of activity, performance or achievements or future events or developments (which could in turn affect the economic benefits derived from KPT's economic interest in Kruger Products) to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the following factors, which are discussed in greater detail in the "Risk Factors - Risks Related to Kruger Products' Business" section of the KPT Annual Information Form dated February 18, 2026 available on SEDAR+ at www.sedarplus.ca (the Annual Information Form): Kruger Inc.'s influence over Kruger Products; Kruger Products' reliance on Kruger Inc.; consequences of an event of insolvency relating to Kruger Inc.; risks associated with the ownership of the TAD Sherbrooke Project; risks associated with the operation of the TAD Sherbrooke Project; operational risks; significant increases in input costs; reduction in supply of fibre; increased pricing pressure and intense competition; Kruger Products' inability to innovate effectively; adverse economic conditions; dependence on key retail trade customers; damage to the reputation of Kruger Products or Kruger Products' brands; Kruger Products' sales being less than anticipated; Kruger Products' failure to implement its business and operating strategies; Kruger Products' obligation to make regular capital expenditures; Kruger Products entering into unsuccessful acquisitions; Kruger Products' dependence on key personnel; Kruger Products' inability to retain its existing customers or obtain new customers; Kruger Products' loss of key suppliers; Kruger Products' failure to adequately protect its intellectual property rights; Kruger Products' reliance on third party intellectual property licenses; adverse litigation and other claims affecting Kruger Products; material expenditures due to comprehensive environmental regulation affecting Kruger Products' cash flow; Kruger Products' pension obligations are significant and can be materially higher than predicted if Kruger Products Management's underlying assumptions are incorrect; labour disputes adversely affecting Kruger Products' cost structure and Kruger Products' ability to run its plants; exchange rate and U.S. competitors; Kruger Products' inability to service all of its indebtedness; exposure to potential consumer product liability; covenant compliance; interest rate and refinancing risk; information technology; cyber-security; insurance; internal controls; trade related and tax.

Readers should not place undue reliance on forward-looking statements made herein. The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. The forward-looking information contained herein is made as of the date of press release and KPT undertakes no obligation to publicly update such forward-looking information to reflect new information, subsequent or otherwise, unless required by applicable securities laws.

INFORMATION:
Francois Paroyan
General Counsel and Corporate Secretary
KP Tissue Inc.
905-812-6936
francois.paroyan@krugerproducts.ca

INVESTORS:
Doris Grbic
Senior Director, Investor Relations
KP Tissue Inc.
437-882-2596
IR@krugerproducts.ca

¹ Adjusted EBITDA is a non-GAAP financial measure. Refer to the Non-GAAP Financial Measures section of this press release for more information on these measures.

Kruger Products Inc.
Unaudited Condensed Consolidated Statements of Financial Position
(thousands of Canadian dollars)
			September 30, 2026			December 31, 2025
			$			$
Assets
Current assets
Cash and cash equivalents			176,407			196,094
Restricted cash			30,150			46,070
Trade and other receivables			165,728			143,313
Receivables from related parties			143			79
Inventories			332,643			284,183
Income tax recoverable			7,271			2,963
Prepaid expenses			12,488			5,381
			724,830			678,083
Non-current assets
Property, plant and equipment			1,421,174			1,430,206
Right-of-use assets			182,958			152,243
Other long-term assets			30,614			498
Pensions			126,158			91,118
Goodwill			152,021			152,021
Intangible assets			38,007			40,362
Deferred income tax asset			51,456			64,671
Total assets			2,727,218			2,609,202
Liabilities
Current liabilities
Trade and other payables			367,033			350,831
Payables to related parties			12,138			13,441
Dividends payable			15,345			14,853
Current portion of long-term debt			89,923			98,649
Current portion of lease liabilities			43,787			43,576
Current portion of long-term payable to related party			5,800			5,800
Current portion of provisions			6,884			7,283
			540,910			534,433
Non-current liabilities
Long-term debt			1,055,242			1,074,646
Long-term lease liabilities			173,471			139,694
Long-term payable to related party			23,579			28,064
Long-term provisions			12,264			12,602
Pensions			18,161			17,745
Post-retirement benefits			46,893			48,333
Deferred income tax liability			72,043			47,140
Total liabilities			1,942,563			1,902,657
Equity
Share capital			346,535			334,479
Contributed surplus			395,382			395,382
Deficit			(96,543)			(151,965)
Accumulated other comprehensive income			95,682			89,343
Equity attributable to Kruger Products			741,056			667,239
Non-controlling interest			43,599			39,306
Total equity			784,655			706,545
Total liabilities and equity			2,727,218			2,609,202

 

Kruger Products Inc.
Unaudited Condensed Consolidated Statements of Income
(thousands of Canadian dollars)
		3-month		3-month		9-month		9-month
		period ended		period ended		period ended		period ended
		September 30, 2026		September 30, 2025		September 30, 2026		September 30, 2025
		$		$		$		$
Revenue		589,655		561,145		1,685,193		1,643,335
Expenses
Cost of sales		481,019		459,988		1,358,064		1,373,175
Selling, general and administrative expenses		48,823		47,906		151,113		146,277
Restructuring costs		-		29		373		3,731
Operating income		59,813		53,222		175,643		120,152
Interest expense and other finance costs		18,707		21,569		58,364		63,826
Other expense (income)		(708)		6,836		10,096		(13,448)
Income before income taxes		41,814		24,817		107,183		69,774
Current tax expense		1,207		242		2,604		2,050
Deferred tax expense		11,122		9,191		30,649		9,274
Income tax expense		12,329		9,433		33,253		11,324
Net income including non-controlling interest		29,485		15,384		73,930		58,450
Net income attributable to non-controlling interest		1,777		838		4,293		6,362
Net income attributable to Kruger Products		27,708		14,546		69,637		52,088

 

Kruger Products Inc.
Unaudited Condensed Consolidated Statements of Cash Flows
(thousands of Canadian dollars)
		3-month		3-month		9-month		9-month
		period ended		period ended		period ended		period ended
		September 30, 2026		September 30, 2025		September 30, 2026		September 30, 2025
		$		$		$		$
Cash flows from (used in) operating activities
Net income including non-controlling interest		29,485		15,384		73,930		58,450
Items not affecting cash
Depreciation		31,448		30,259		89,637		103,875
Amortization		2,233		2,190		5,366		6,170
Loss (gain) on sale of property, plant and equipment		1		-		1		(5)
Loss (gain) on disposal of leased assets		(3)		-		(3)		23
Fair value gain on derivative asset		(174)		-		(174)		-
Foreign exchange loss (gain)		(534)		6,836		10,270		(13,448)
Interest expense and other finance costs		18,707		21,569		58,364		63,826
Pension and post-retirement benefits		2,730		2,844		8,130		8,417
Provisions		2,108		1,930		5,294		5,859
Income tax expense		12,329		9,433		33,253		11,324
Total items not affecting cash		68,845		75,061		210,138		186,041
Net change in non-cash working capital		(11,983)		25,096		(71,042)		(29,471)
Contributions to pension and post-retirement benefit plans		712		(869)		(1,308)		(2,884)
Provisions paid		(93)		(655)		(7,230)		(4,679)
Income tax payments, net		(497)		(681)		(1,743)		(2,492)
Net cash from operating activities		86,469		113,336		202,745		204,965
Cash flows from (used in) investing activities
Purchases of property, plant and equipment		(19,411)		(13,451)		(48,208)		(23,313)
Purchases of property, plant and equipment related to the
Sherbrooke Expansion Project		(664)		(1,796)		(2,344)		(19,173)
Government assistance received		-		(31)		3,497		3,119
Investment in derivative asset		(1,027)		-		(28,875)		-
Purchase of software		(2,500)		(989)		(3,017)		(2,083)
Net cash used in investing activities		(23,602)		(16,267)		(78,947)		(41,450)
Cash flows from (used in) financing activities
Proceeds from long-term debt		-		(22,017)		-		9,171
Repayment of long-term debt		(20,457)		(16,613)		(54,210)		(49,118)
Payment of deferred financing fees		(230)		(30)		(1,057)		(23)
Payment of lease liabilities		(11,466)		(8,738)		(31,051)		(25,475)
Change in restricted cash		(1,716)		31,680		15,920		3,730
Interest paid on long-term debt		(6,784)		(9,975)		(35,628)		(41,396)
Payment to related party		-		-		(5,800)		(5,800)
Dividends paid		(15,289)		(14,596)		(45,065)		(43,352)
Proceeds from issuing partnership units		4,016		6,461		11,997		19,147
Net cash used in financing activities		(51,926)		(33,828)		(144,894)		(133,116)
Effect of exchange rate changes on cash and cash
equivalents held in foreign currency		243		583		1,409		(728)
Increase (decrease) in cash and cash equivalents
during the period		11,184		63,824		(19,687)		29,671
Cash and cash equivalents - Beginning of period		165,223		85,307		196,094		119,460
Cash and cash equivalents - End of period		176,407		149,131		176,407		149,131

 

Kruger Products Inc.
Unaudited Segment and Geographic Results
(thousands of Canadian dollars)
		3-month		3-month		9-month		9-month
		period ended		period ended		period ended		period ended
		September 30, 2026		September 30, 2025		September 30, 2026		September 30, 2025
		$		$		$		$
Segment Information
Segment Revenue
Consumer		492,774		468,313		1,412,063		1,382,725
AFH		96,881		92,832		273,130		260,610
Revenue from external customers		589,655		561,145		1,685,193		1,643,335
Other segment items
Consumer		404,804		390,069		1,154,850		1,159,245
AFH		87,932		82,453		249,370		238,479
Corporate and other costs		3,426		2,922		9,953		11,665
Total other segment items		496,162		475,444		1,414,173		1,409,389
Adjusted EBITDA
Consumer		87,970		78,244		257,213		223,480
AFH		8,949		10,379		23,760		22,131
Corporate and other costs		(3,426)		(2,922)		(9,953)		(11,665)
Total Adjusted EBITDA		93,493		85,701		271,020		233,946
Reconciliation to net income (loss)
Depreciation and amortization		33,679		32,450		95,003		110,045
Interest expense and other finance costs		18,707		21,569		58,364		63,826
Loss on disposal of property, plant and equipment		1		-		1		18
Restructuring costs, net		-		29		373		3,731
Other income		(174)		-		(174)		-
Foreign exchange loss (gain)		(534)		6,836		10,270		(13,448)
Income before income taxes		41,814		24,817		107,183		69,774
Income tax expense		12,329		9,433		33,253		11,324
Net income including non-controlling interest		29,485		15,384		73,930		58,450
Geographic Revenue
Canada		311,069		301,360		891,933		889,217
US		278,586		259,785		793,260		754,118
Total revenue		589,655		561,145		1,685,193		1,643,335

 

 

KP Tissue Inc.
Unaudited Condensed Statements of Financial Position
(thousands of Canadian dollars)
		September 30, 2026			December 31, 2025
		$			$
Assets
Current assets
Dividends receivable		2,107			1,803
		2,107			1,803
Non-current assets
Investment in associate		76,293			69,799
Total assets		78,400			71,602
Liabilities
Current liabilities
Dividends payable		2,107			1,803
Total liabilities		2,107			1,803
Equity
Common shares		23,194			23,001
Contributed surplus		144,819			144,819
Deficit		(109,511)			(114,985)
Accumulated other comprehensive income		17,791			16,964
Total equity		76,293			69,799
Total liabilities and equity		78,400			71,602

 

KP Tissue Inc.
Unaudited Condensed Statements of Income
(thousands of Canadian dollars, except share and per share amounts)
		3-month		3-month		9-month		9-month
		period ended		period ended		period ended		period ended
		September 30, 2026		September 30, 2025		September 30, 2026		September 30, 2025
		$		$		$		$
Share of income		3,310		1,700		8,359		6,372
Depreciation of fair value increments		(269)		(264)		(808)		(827)
Equity income		3,041		1,436		7,551		5,545
Dilution gain		59		114		171		323
Net income		3,100		1,550		7,722		5,868
Basic and diluted earning per share		0.31		0.15		0.77		0.59
Weighted average number of shares outstanding		10,031,675		10,007,057		10,026,643		10,000,087

 

KP Tissue Inc.
Unaudited Statements of Cash Flows
(thousands of Canadian dollars)
		3-month		3-month		9-month		9-month
		period ended		period ended		period ended		period ended
		September 30, 2026		September 30, 2025		September 30, 2026		September 30, 2025
		$		$		$		$
Cash flows from (used in) operating activities
Net income		3,100		1,550		7,722		5,868
Items not affecting cash
Equity income		(3,041)		(1,436)		(7,551)		(5,545)
Dilution gain		(59)		(114)		(171)		(323)
Total items not affecting cash		(3,100)		(1,550)		(7,722)		(5,868)
Net cash from operating activities		-		-		-		-
Cash flows from (used in) investing activities
Dividends received, net		2,046		1,739		5,522		5,229
Net cash from investing activities		2,046		1,739		5,522		5,229
Cash flows from (used in) financing activities
Dividends paid, net		(2,046)		(1,739)		(5,522)		(5,229)
Net cash used in financing activities		(2,046)		(1,739)		(5,522)		(5,229)
Increase in cash and cash equivalents during the period		-		-		-		-
Cash and cash equivalents - Beginning of period		-		-		-		-
Cash and cash equivalents - End of period		-		-		-		-

 

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/322858

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were KP Tissue's Q3 2026 earnings?

KP Tissue reported $3.1 million in net income for Q3 2026. This included $3.3 million representing its share of Kruger Products' net income, a $0.1 million dilution gain and $0.3 million of depreciation related to acquisition carrying-value adjustments.

When will KP Tissue pay its quarterly dividend, and who qualifies?

KP Tissue will pay its $0.21-per-share quarterly dividend on January 15, 2027 to shareholders of record at the close of business on December 31, 2026.

How much liquidity did Kruger Products have at the end of Q3 2026?

Kruger Products had $434.2 million in total liquidity as of September 30, 2026. This comprises cash and availability under its revolving credit agreements.